Comparative Analysis of Antifibrotic and Anti-inflammatory Effects of Metformin and Canagliflozin in Lung Fibrosis Models
DOI:
https://doi.org/10.48047/kw6se264Keywords:
Antifibrotic and Anti-inflammatory, Metformin and Canagliflozin , Lung Fibrosis ModelsAbstract
This study investigates the comparative antifibrotic and anti-inflammatory effects of metformin and canagliflozin in lung fibrosis models, focusing on the potential effect of canagliflozin to mitigate fibrosis-related molecular and histopathological changes. Aim: To evaluate the efficacy of metformin and canagliflozin in mitigating lung fibrosis and associated pulmonary complications in rat models by assessing their effects on SMAD2/3 signaling pathways, inflammatory markers, oxidative stress parameters, and histopathological alterations. Methods: This study utilized 40 adult male albino rats, divided into four groups: normal control, lung fibrosis control, metformin-treated lung fibrosis, and canagliflozin-treated lung fibrosis. Lung fibrosis was induced by intratracheal instillation of bleomycin. Treatments included oral metformin (50 mg/kg/day) or canagliflozin (40 mg/kg/day) for 14 days. Biochemical parameters, including fasting blood glucose (FBG), advanced glycation end products (AGE), lactate dehydrogenase (LDH), and protein content in bronchoalveolar lavage fluid (BALF), were measured. Histopathological and immunohistochemical analyses were performed on lung tissues to evaluate fibrosis markers, such as TGF-β expression and SMAD2/3 signaling.
Downloads
References
Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic pulmonary fibrosis (IPF) and the elderly patient: diagnosis and management. Front Med (Lausanne). 2018;5:148. doi:10.3389/fmed.2018.00148.
Cox MJ, McErlean P, Moffatt MF, Cookson WO. Genetic variation in TOLLIP and susceptibility to idiopathic pulmonary fibrosis. N Engl J Med. 2022;366(21):19611969. doi:10.1056/NEJMoa1104585.
Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811-1823. doi:10.1056/NEJMra1705751.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
